• CVRX

Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins

CVRx Q3 2024 revenue rose 27% to $13.4 million, despite a net loss of $13.1 million, while aiming to make Barostim therapy a standard care option.